Nerivio Wearable demonstrates Sustained Migraine Relief Over 3 Years, New Data Show
Table of Contents
New data presented at the 2025 American Headache Society (AHS) Annual Meeting reinforce the long-term efficacy and safety of Nerivio®, a remote electrical neuromodulation (REN) wearable device for both acute and preventive migraine treatment in patients aged 8 years and older. The findings highlight consistent pain relief, functional recovery, and freedom from migraine-associated symptoms over a three-year period, with no evidence of tachyphylaxis – a common concern with many migraine therapies.
Long-Term Efficacy and Absence of Tachyphylaxis
Theranica‘s research, unveiled at AHS 2025 in Minneapolis, Minnesota, provides compelling evidence supporting Nerivio as a durable, non-pharmacologic option for migraine management.A key study prospectively tracked patients on a month-to-month basis, collecting real-time data on device usage and treatment outcomes. This prospective data collection methodology strengthens the reliability of the findings.
The results demonstrated that the REN wearable maintained consistent efficacy throughout the three-year study duration. Patients reported sustained pain relief, improved functional abilities, and resolution of migraine-related symptoms without requiring increased stimulation intensity. This lack of need for escalation suggests the absence of tachyphylaxis, a phenomenon where the body becomes less responsive to a treatment over time.
“The long-term data adds value to support the viability of Nerivio as a durable nonpharmacologic option in migraine care,” explained Alit Stark-Inbar, PhD, corporate vice president of medical facts and research at Theranica, in an interview with NeurologyLive® following the AHS presentations. Dr. Stark-Inbar emphasized the importance of the prospective, monthly data collection in providing a robust assessment of real-world effectiveness.
Similar Efficacy in migraine With and Without Aura
Beyond the long-term efficacy study,Theranica also presented research comparing Nerivio’s impact on migraine sufferers with and without aura. Analyzing data from nearly 32,000 patients, the study revealed that while those with aura initially presented with more severe symptoms, their treatment outcomes were comparable to, and in some instances slightly better than, those without aura.
Both groups experienced significant improvements in pain relief, functional recovery, and the resolution of migraine-related symptoms.This finding broadens the potential applicability of Nerivio, suggesting it can effectively address migraine nonetheless of the presence of aura.
Understanding Migraine Aura and Treatment Implications
Migraine aura is a neurological phenomenon preceding or accompanying a migraine headache, frequently enough manifesting as visual disturbances, sensory changes, or speech difficulties. historically, treatment approaches have sometimes differed based on whether aura is present. The Theranica study’s finding of comparable efficacy across both groups is significant, suggesting a more global treatment approach might potentially be possible with Nerivio. This is notably valuable as diagnosing aura can sometimes be challenging, and a treatment effective for both presentations simplifies clinical decision-making.
Nerivio: A Non-Drug Alternative for Migraine Management
these recent data collectively position Nerivio as a valuable non-drug alternative for individuals seeking relief from migraine. The device utilizes REN technology to stimulate peripheral nerves, modulating pain signals and offering a possibly effective treatment option without the systemic side effects frequently enough associated with pharmaceutical interventions.
The prospective, real-world evidence presented at AHS 2025 strengthens the clinical confidence in Nerivio’s long-term benefits and broad applicability across different migraine presentations. For patients seeking a durable, non-pharmacologic solution, Nerivio offers a promising avenue for managing both acute attacks and preventing future episodes.
REFERENCES
- Nahas SJ, Birlea M, Stark-Inbar A, et al. Remote Electrical Neuromodulation (REN) Shows Consistent Efficacy without tachyphylaxis Over three Years of Treatment. Presented at: 2025 AHS Annual Meeting; June 19-22; Minneapolis, MN.
- Theranica to Present Three Real-World Evidence Studies at AHS Scientific Meeting Highlighting the Impact of the Nerivio® REN Wearable on Migraine Treatment. News Release. Theranica.Published June 19, 2025. Accessed August 6, 2025. https://www.nerivio.com/news-press/theranica-to-present-three-real-world-evidence-studies-at-ahs-scientific-meeting-highlighting-the-impact-of-the-nerivio-r-ren-wearable-on-migraine-
